The earnings season crunch is upon us once again, and among those companies reporting next week are Altria Group Inc. (NYSE: MO) and Pfizer Inc. (NYSE: PFE).
In its second quarter report in July, Atria reported earnings per share of $1.15, beating Wall Street's expectations by a couple of pennies. However, Altria has had five-year earnings per share growth of only 1.9 percent, well below the tobacco industry average and the S&P 500. For the third quarter, analysts surveyed by Thomson Financial expect Intel to report EPS of $1.14, about the same as last quarter, and less than the $1.39 actual EPS from the same period last year.
Yet, the handful of analysts surveyed by Thomson Financial recommend buying Altria: two rate it a strong buy, six a buy, and four a hold. Altria's share price is up from a 52-week low of $63.13 in July, but well off of its 52-week high of $90.50 in January. It closed Friday at $70.06.
For more on Supreme Court decisions, cigarette taxes, and other news that might affect Altria's quarterly report, check out BloggingStocks' Altria coverage.
Pfizer missed analysts' EPS expectations by seven cents when it reported second quarter results back in July. Before that, Pfizer had beat Wall Street expectations in the previous eight quarters. Analysts surveyed by Thomson Financial expect earnings per share of 52 cents for the third quarter, up from 42 cents actual in the second quarter, and a couple of pennies lower than in the same quarter a year ago. The EPS growth of 4.8 percent over the past year is only about half of the pharmaceutical industry average, and less than the S&P 500.
The consensus of analysts surveyed by Thomson Financial has shifted from buy to hold PFE in the past month, 14 of them now saying hold, but only 6 buy or strong buy. Pfizer's share price has struggled to rise from a 52-week low of $23.13 in August, and closed Friday at $25.26.
For more on Pfizer's new R&D chief and news about rivals that could affect Pfizer's quarterly report, see BloggingStocks' Pfizer coverage.
Altria reports earnings on Wednesday, Pfizer on Thursday.